PrintFriendly

Print Friendly, PDF & Email

Hemlibra Safety Update

May 21, 2018
Novo Nordisk Announces BLA Submission for Extended Half-Life FVIII Therapy

Genentech informed NHF of an unrelated postmarketing fatality that has occurred in an elderly patient who received treatment with emicizumab- kxwh (Hemlibra) for acquired hemophilia A. The cause of death was assessed by the treating physician to be sudden cardiac death, unrelated to emicizumab-kxwh. This event occurred outside of the US.

Recently Genentech launched a web portal for healthcare providers. This portal provides up to date safety information on Hemlibra.

Genentech has shared that a similar web portal for patients is currently being developed and is forthcoming. NHF will continue to provide updated information as it becomes available.

NHF does not recommend, endorse or make any representation about the efficacy, appropriateness or suitability of any specific products, treatments, or opinions. Please consult your physician before use of any treatments.